Coronary CTA Superior to Standard Care in Stable Chest Pain
Coronary computed tomographic angiography was associated with a lower 5-year mortality rate in patients with stable chest pain.
ESC 2018 Meeting Highlights
SAVR vs TAVR: Adverse Outcomes Risk in Aortic Stenosis
Surgical and transcatheter aortic valve replacement had a similar risk for adverse outcomes in patients with severe aortic stenosis, regardless of whether or not the patients had prior cardiac surgery.
Outcomes With Rivaroxaban in Chronic Heart Failure With Underlying CAD
Rivaroxaban was not superior to placebo for reducing the rate of death, MI, or stroke in patients with chronic heart failure.
Tafamidis Reduces Mortality, Hospitalizations in Transthyretin Amyloid Cardiomyopathy
Tafamidis was associated with reduced all-cause mortality and cardiovascular-related complications in patients with transthyretin amyloid cardiomyopathy.
Statins, CCBs Confer Long-Term Mortality Benefit in Hypertension
Mortality benefits from atorvastatin- and amlodipine-based antihypertensive treatments extend beyond 10 years of treatment.
Ticagrelor Without Concomitant Aspirin No Better Than Standard DAPT in PCI
Ticagrelor without aspirin offered no additional benefits compared with conventional dual antiplatelet therapy in patients undergoing PCI for either CAD or ACS.
Radial Access Reduced Adverse Events in Intervention for Acute Coronary Syndrome
Net adverse cardiac events occurred in 15.2% of patients with radial access and 17.2% with femoral access while undergoing invasive therapies for acute coronary syndrome.
Coronary CTA Associated With Lower Death Rate in CHD, Nonfatal MI
There was a lower death rate from coronary heart disease and non-fatal MI at 5 years in patients with stable chest pain.
VKA vs Non-VKA Oral Anticoagulants: Mortality Rates Compared in AF
The new analysis included 19,134 of these patients and showed that there were 19% fewer deaths in patients initiated on NOACs compared to VKAs at the time of AF diagnosis.
Does Aspirin Cut the Risk of Initial Vascular Events in Patients at Moderate CVD Risk?
For this double-blind, placebo-controlled study, researchers selected male patients ≥55 years and female patients ≥60 years with average cardiovascular risk and assigned them to enteric-coated aspirin 100mg (N=6270) or placebo (N=6276) once daily; the median follow-up time was 60 months.
Want to read more?
Please login or register first to view this content.
Next post in ESC 2018 Meeting Highlights
